| Mark D Johnson, MD | |
|
255 Plain Drive, Massachusetts Anesthesia Corp., Stoughton, MA 02072-0372 | |
| (781) 341-3966 | |
| (781) 341-8269 |
| Full Name | Mark D Johnson |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 255 Plain Drive, Stoughton, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770518581 | NPI | - | NPPES |
| 050092266 | Other | RAILROAD MEDICARE | |
| 6171433 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 48521 (Massachusetts) | Primary |
| Entity Name | Anesthesia Professionals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659346443 PECOS PAC ID: 0042297582 Enrollment ID: O20040702000303 |
News Archive
About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis.
Politico: "Senate Minority Leader Mitch McConnell told Republicans Tuesday that he plans to force a vote on repealing the health care reform law this week. The plan is to tack the amendment onto the Federal Aviation Administration reauthorization bill this afternoon, a Republican aide told POLITICO. McConnell told Republicans of the plan in their weekly policy lunch" (Haberkorn, 2/1).
By studying the genetic make up of a German boy born with unusually well developed muscles, an international research team has discovered the first evidence that the gene whose loss makes "mighty mice" also controls muscle growth in people.
Trust for America's Health applauds the action of the United States House of Representatives, which passed the Patient Protection and Affordable Care Act late last night. The bill expands coverage to millions of uninsured Americans, establishes a national prevention strategy, and creates a reliable funding stream through the creation of a Public Health Investment Fund.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.
› Verified 5 days ago
| Entity Name | Ivs Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740440163 PECOS PAC ID: 9537233010 Enrollment ID: O20081201000530 |
News Archive
About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis.
Politico: "Senate Minority Leader Mitch McConnell told Republicans Tuesday that he plans to force a vote on repealing the health care reform law this week. The plan is to tack the amendment onto the Federal Aviation Administration reauthorization bill this afternoon, a Republican aide told POLITICO. McConnell told Republicans of the plan in their weekly policy lunch" (Haberkorn, 2/1).
By studying the genetic make up of a German boy born with unusually well developed muscles, an international research team has discovered the first evidence that the gene whose loss makes "mighty mice" also controls muscle growth in people.
Trust for America's Health applauds the action of the United States House of Representatives, which passed the Patient Protection and Affordable Care Act late last night. The bill expands coverage to millions of uninsured Americans, establishes a national prevention strategy, and creates a reliable funding stream through the creation of a Public Health Investment Fund.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark D Johnson, MD Po Box 372, Massachusetts Anesthesia Corp., Stoughton, MA 02072-0372 Ph: (781) 341-3966 | Mark D Johnson, MD 255 Plain Drive, Massachusetts Anesthesia Corp., Stoughton, MA 02072-0372 Ph: (781) 341-3966 |
News Archive
About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis.
Politico: "Senate Minority Leader Mitch McConnell told Republicans Tuesday that he plans to force a vote on repealing the health care reform law this week. The plan is to tack the amendment onto the Federal Aviation Administration reauthorization bill this afternoon, a Republican aide told POLITICO. McConnell told Republicans of the plan in their weekly policy lunch" (Haberkorn, 2/1).
By studying the genetic make up of a German boy born with unusually well developed muscles, an international research team has discovered the first evidence that the gene whose loss makes "mighty mice" also controls muscle growth in people.
Trust for America's Health applauds the action of the United States House of Representatives, which passed the Patient Protection and Affordable Care Act late last night. The bill expands coverage to millions of uninsured Americans, establishes a national prevention strategy, and creates a reliable funding stream through the creation of a Public Health Investment Fund.
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.
› Verified 5 days ago
Peter Joseph Calkin, D.O. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 907 Sumner St, Suite M201, Stoughton, MA 02072 Phone: 781-344-2325 Fax: 781-341-8544 | |
Glen Shaw Ni, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 907 Sumner St, Guardian Anesthesia Inc, Stoughton, MA 02072 Phone: 781-344-2325 Fax: 781-341-8544 | |
Peter Andersen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 907 Sumner St., M201, Stoughton, MA 02072 Phone: 781-344-2325 Fax: 781-341-8544 | |
Dr. Anna Margulian, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 907 Sumner St. M201, Guardian Anesthesia Inc., Stoughton, MA 02072 Phone: 781-344-2325 Fax: 781-341-8544 | |
Andrew Gutowski, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 907 Sumner St, M201, Stoughton, MA 02072 Phone: 781-344-2325 Fax: 781-341-8544 | |
Dr. Neil W Oliwa, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 907 Sumner Street, M201, Guardian Anesthesia Inc., Stoughton, MA 02072 Phone: 781-344-2325 Fax: 781-341-8544 | |
Ahmed M. Atia, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 907 Sumner St, M201, Stoughton, MA 02072 Phone: 508-941-7000 |